Invikafusp Alfa: New Hope for Advanced, Anti-PD-1 Resistant Cancers Phase 1 and 2 Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Hope for Hard-to-Treat Cancers: a New TACC3 Inhibitor
/in Clinical Trial, Not PCa related/by MaxSequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxB7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/in Clinical Trial, Phase 1/by MaxOP-3136: New Drug Receives FDA Clearance to Begin Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxPromising Results for B7-H3 Antibody-Drug Conjugate in Advanced Solid Tumors (including metastatic castration resistant prostate cancer)
/in Clinical Trial, Metastatic, Phase 1/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
- UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals June 9, 2026
- BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap June 9, 2026